Pangea Therapeutics Ltd.
Pangea Biomed, founded in 2018, is on a mission to democratize precision oncology by leveraging its proprietary ENLIGHT platform, which combines advanced molecular biology technology with bioinformatics and machine learning. The platform enables a deeper understanding of tumor responses to therapies by analyzing not just genomic abnormalities but also expression and epigenetic factors. This comprehensive approach allows for highly personalized treatment recommendations, improving clinical outcomes and efficiency in drug development. Pangea collaborates with leading medical institutions and research labs, positioning itself as a key player in the precision oncology market.
Pangea Therapeutics Ltd.
Pangea Biomed, founded in 2018, is on a mission to democratize precision oncology by leveraging its proprietary ENLIGHT platform, which combines advanced molecular biology technology with bioinformatics and machine learning. The platform enables a deeper understanding of tumor responses to therapies by analyzing not just genomic abnormalities but also expression and epigenetic factors. This comprehensive approach allows for highly personalized treatment recommendations, improving clinical outcomes and efficiency in drug development. Pangea collaborates with leading medical institutions and research labs, positioning itself as a key player in the precision oncology market.